Ankylosing Spondylitis Market Report Scope & Overview:

The Ankylosing Spondylitis Market was valued at USD 6.68 Billion in 2025 and is expected to reach USD 13.88 Billion by 2035, growing at a CAGR of 7.59% from 2026–2035.

Ankylosing spondylitis is a chronic, inflammatory form of arthritis that mainly targets the spine and sacroiliac joints, and over time it can fuse vertebrae together and leave patients with reduced mobility and lasting pain. It tends to show up in a person's twenties or thirties, which means most people living with it face decades of ongoing management rather than a short course of treatment. That reality shapes the market in a pretty direct way: patients need therapies they can stay on for years, and pharmaceutical companies have responded by building out an increasingly crowded field of biologics, JAK inhibitors, and older standbys like NSAIDs that still get prescribed constantly because they're cheap and they work well enough for milder cases. Better imaging and more awareness among primary care doctors have also meant that people are getting diagnosed earlier than they used to, which matters because starting biologic treatment before the disease progresses too far tends to produce much better long-term outcomes.

In September 2024, the FDA approved UCB's Bimzelx (bimekizumab) for active ankylosing spondylitis and non-radiographic axial spondyloarthritis, based on results from the BE MOBILE 1 and BE MOBILE 2 Phase 3 trials. Bimzelx works by blocking both IL-17A and IL-17F, a dual-inhibition approach that sets it apart from earlier interleukin inhibitors on the market, and its approval gives rheumatologists another option for patients who haven't responded well to TNF inhibitors or who need a different mechanism of action altogether.

Market Size and Forecast

• Market Size in 2026E: USD 7.19 Billion

• Market Size by 2035: USD 13.88 Billion

• CAGR: 7.59% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get more information on Ankylosing Spondylitis Market - Request Free Sample Report

Ankylosing Spondylitis Market Trends

• Dual-mechanism biologics that target more than one inflammatory pathway at once are starting to reshape treatment guidelines, giving physicians more room to switch patients who've plateaued on older TNF inhibitors.

• Biosimilar competition is heating up as patents on early biologics like Humira keep expiring, and insurers are increasingly steering patients toward these lower-cost alternatives first.

• JAK inhibitors, taken as a daily pill rather than an injection, are gaining ground with patients who'd rather avoid needles, even though they come with their own set of safety warnings that keep some physicians cautious.

• MRI-based diagnostic protocols are catching non-radiographic axial spondyloarthritis earlier than X-ray ever could, which is gradually shifting more of the patient population into treatment sooner.

• Patient support programs run directly by drug manufacturers, covering everything from injection training to copay assistance, have become a real factor in which biologic a newly diagnosed patient ends up on.

U.S. Ankylosing Spondylitis Market Outlook

The U.S. Ankylosing Spondylitis Market was valued at approximately USD 3.08 Billion in 2025 and is expected to reach approximately USD 6.24 Billion by 2035, growing at a CAGR of approximately 7.33%.

The U.S. is, by a wide margin, the largest single national market for ankylosing spondylitis treatment, and it isn't hard to see why. Biologic uptake is higher here than almost anywhere else, insurance coverage (for those who have it) tends to be more generous toward specialty drugs than in most countries, and the rheumatology infrastructure, meaning enough specialists to actually diagnose and manage the disease properly, is simply more built out. AbbVie, Johnson & Johnson, and Amgen all run their biggest clinical programs domestically, and new therapies typically launch in the U.S. before they reach other markets. None of that is guaranteed to continue at the same pace, though; drug pricing pressure from payers and from Washington is a real variable that could change how quickly newer, pricier biologics get adopted going forward.

In October 2024, Johnson & Johnson took over full responsibility for marketing and distributing Remicade and Simponi in the United Kingdom, a shift that consolidates the company's control over two of its longer-standing biologics used across ankylosing spondylitis, rheumatoid arthritis, and several other inflammatory conditions. While this particular move centers on the UK market, it reflects a broader pattern among large pharmaceutical companies of tightening direct control over legacy biologic franchises as biosimilar competition intensifies and margins on older products come under pressure.

Ankylosing Spondylitis Market Segment Analysis

• By Treatment, the NSAIDs segment dominated the Ankylosing Spondylitis Market with a 48.10% revenue share in 2025, while Biologic Therapies is the fastest growing segment.

• By Route of Administration, the Parenteral segment dominated the Ankylosing Spondylitis Market with a 57.46% revenue share in 2025, while the Oral segment is the fastest growing.

• By Type, the Prescription Drugs segment dominated the Ankylosing Spondylitis Market with a 78.51% revenue share in 2025.

• By Application, the Adults segment dominated the Ankylosing Spondylitis Market with an 88.14% revenue share in 2025, while the Juveniles segment is the fastest growing.

• By Distribution Channel, the Hospital Pharmacies segment dominated the Ankylosing Spondylitis Market with a 47.15% revenue share in 2025, while the Online Pharmacies segment is the fastest growing.

By Treatment, NSAIDs still lead, but biologics are closing the gap fast

NSAIDs held onto about 48% of the treatment market in 2025, and honestly, that's not surprising once you think about how AS actually gets managed day to day. Ibuprofen and naproxen are cheap, they're available over the counter in most places, and for a lot of patients with milder disease they do a perfectly reasonable job of knocking down inflammation and stiffness. Doctors also tend to prescribe them alongside biologics rather than instead of them, which keeps demand steady even as more advanced options crowd into the market.

Biologic therapies are where the real growth is happening, though. Drugs like Humira and Cosentyx don't just mask symptoms the way NSAIDs do, they actually change the disease course for a meaningful share of patients, and that difference matters enormously to someone facing a lifetime diagnosis. As more biologics come off patent and biosimilar versions bring prices down, access is widening in exactly the markets where cost used to be the main barrier, and that combination of better outcomes and improving affordability is what's pushing this segment's growth well ahead of the overall market.

By Route of Administration, parenteral dominates, but oral options are gaining fast

Parenteral administration, meaning injections or infusions, accounted for roughly 57% of the market in 2025, largely because that's how most biologics have to be delivered to work properly. Drugs like Humira and Simponi need to get straight into the bloodstream to hit their target inflammatory pathways effectively, and for moderate to severe AS, that level of efficacy is worth the inconvenience of a needle for most patients.

Oral treatment is growing faster, though, driven almost entirely by JAK inhibitors, which come as a daily pill instead of an injection. Not everyone loves needles, unsurprisingly, and a once-a-day tablet is a much easier thing to build into a routine than a biweekly injection appointment. As more JAK inhibitors clear regulatory review and physicians get more comfortable prescribing them, this segment should keep picking up share, even if parenteral biologics remain the backbone of moderate-to-severe disease management for now.

By Type, prescription drugs dominate

Prescription medications made up close to 79% of the market in 2025, which reflects just how much of effective AS treatment depends on drugs that require a doctor's involvement. Biologics and DMARDs aren't things you can pick up at a pharmacy counter without a prescription, and they're specifically designed to interrupt the immune system processes driving the disease, something OTC pain relievers simply aren't built to do.

As more patients get pushed toward biologics and JAK inhibitors rather than sticking with basic NSAID management, prescription drugs are likely to keep their dominant position, if not extend it further. OTC options will always have a role for mild symptom relief, but they're not where the clinical or commercial action is in this market.

By Application, adults dominate, but juvenile diagnoses are rising

Adults made up about 88% of the market in 2025, which lines up with what's known about the disease itself: AS typically shows up between someone's late teens and their forties, and the chronic nature of the condition means adult patients accumulate years, sometimes decades, of ongoing treatment costs that juvenile cases simply don't generate at the same scale yet.

Juvenile cases are the fastest-growing application segment, even from a much smaller base, as pediatric rheumatologists get better at recognizing early spondyloarthritis symptoms that used to get missed or misattributed to growing pains. Earlier pediatric diagnosis means earlier treatment, and as awareness continues to spread among pediatricians and family doctors who see these patients first, this segment should keep expanding faster than the adult population, even though adults will remain the larger revenue base by far.

By Distribution Channel, hospital pharmacies dominate, online pharmacies grow fastest

Hospital pharmacies handled about 47% of distribution in 2025, largely because a lot of biologic administration, especially IV infusions, has to happen under clinical supervision. Patients on more advanced treatment regimens often need monitoring that only a hospital or specialty infusion center can realistically provide, which keeps this channel central to how the more expensive end of AS treatment gets delivered.

Online pharmacies are growing the fastest, as more patients on stable, self-administered injectable regimens shift toward the convenience of home delivery rather than routine pharmacy visits. This shift picked up noticeably after telehealth became more mainstream, and it's continued even as in-person healthcare has largely normalized again, suggesting patients simply prefer the convenience once they've tried it.

Regional Analysis

North America Ankylosing Spondylitis Market Insights

North America dominated the ankylosing spondylitis market in 2025 with just over 56% of global revenue, and a few things explain that lead pretty clearly: strong insurance reimbursement for specialty drugs, high disease awareness among both patients and physicians, and a healthcare system with enough rheumatologists to actually catch and manage the condition properly. AbbVie, Johnson & Johnson, and Amgen all have deep roots here, and new biologics and JAK inhibitors tend to launch in this market first.

The high background rate of autoimmune and inflammatory disease diagnosis in the region, paired with easy access to imaging and specialist referrals, keeps reinforcing that lead. Steady government funding for autoimmune disease research and a consistent pipeline of FDA approvals add further momentum, and Canada contributes a smaller but stable share through its own public healthcare system's coverage of biologic therapies.

Get Customized Report as per Your Business Requirement - Enquiry Now

Asia Pacific Ankylosing Spondylitis Market Insights

Asia Pacific is the fastest-growing regional market, with a CAGR of around 8.10% expected through 2035. Rising healthcare spending, a large and still-underdiagnosed patient population, and growing awareness of AS as a distinct, treatable condition (rather than just chronic back pain) are all pushing this growth. China, India, and South Korea are seeing meaningfully higher early-diagnosis rates as government health programs expand insurance coverage and bring biologics within reach of more patients.

The sheer size of the region's population, combined with rising rates of autoimmune conditions tied to lifestyle changes, means there's a lot of unmet need still to be addressed. As local biosimilar manufacturers keep scaling up production and driving costs down, access should keep widening further, and that combination of demand and improving affordability is exactly why this region is expected to keep growing faster than any other.

Europe Ankylosing Spondylitis Market Insights

Europe is a mature, well-established ankylosing spondylitis market, shaped by universal healthcare systems that generally cover biologic treatment once it's clinically justified, alongside a long tradition of rheumatology research. Germany leads regional demand, backed by a strong domestic pharmaceutical industry and a healthcare system that gets patients to specialists relatively quickly compared to many other countries.

The UK, France, and Italy round out the region's demand, and European regulators have generally been quick to approve new biosimilars, which has kept treatment costs more manageable than in the U.S. even as newer biologics and JAK inhibitors continue entering the market. That combination of steady biosimilar approvals and comprehensive coverage should keep the region growing at a measured, if unspectacular, pace.

MEA & Latin America Ankylosing Spondylitis Market Insights

The Middle East and Africa remain an earlier-stage ankylosing spondylitis market, with Saudi Arabia leading regional demand as the country expands its healthcare infrastructure and rheumatology specialist base under its broader Vision 2030 healthcare reform agenda. South Africa contributes meaningfully within the African market, largely through its more established private healthcare sector.

Latin America is seeing gradual but real growth, led by Brazil, where public healthcare investment and growing rheumatology capacity are slowly improving both diagnosis rates and treatment access. Mexico follows as the region's second-largest market, though affordability remains a bigger constraint here than in North America or Europe, which keeps biosimilar adoption an important part of how access continues to expand.

Market Dynamics

Growth Drivers: Biologic adoption and earlier diagnosis are reshaping how AS gets treated

The single biggest driver behind this market's growth is simply how much better biologics have gotten at controlling the disease. TNF inhibitors and interleukin inhibitors like Humira and Cosentyx have genuinely changed what an AS diagnosis means for a patient's long-term mobility and quality of life, and that's not marketing language, it shows up clearly in outcomes data. As more biologics enter clinical trials and reach approval, physicians and patients alike keep gravitating toward these options over older conventional DMARDs, and that preference alone is pulling a growing share of revenue toward the biologic segment.

Earlier diagnosis is the other half of the story. AS has always been notoriously easy to miss in its early stages because the symptoms, back pain and stiffness, look like a hundred other things. Better imaging protocols and more awareness among primary care physicians and rheumatologists are catching more cases sooner, and government and nonprofit screening initiatives targeting at-risk groups are adding to that trend. Starting biologic treatment earlier tends to prevent the kind of chronic joint damage that's much harder to manage once it's set in, which is exactly why this shift toward earlier detection keeps reinforcing demand for treatment across the board.

Restraints: Biologic pricing keeps real patients from getting real treatment

The most obvious restraint in this market is cost, and it's a genuinely serious one. Biologics like Humira, Simponi, and Cosentyx work well, but they're expensive, often prohibitively so for patients without comprehensive insurance or in countries where healthcare systems can't absorb that cost at scale. That price tag doesn't just limit access, it puts real financial strain on both patients and the broader healthcare systems trying to cover them.

Access is also uneven in ways that track pretty predictably with income and geography. Patients in rural areas or in countries with less developed healthcare funding often simply can't get the treatment that would help them most, and when that happens, the disease tends to progress further than it needs to. That gap between what's clinically available and what's actually reachable for a given patient remains one of the more stubborn problems holding back faster overall market growth.

Opportunities: Biosimilars are turning cost from a barrier into a growth engine

As patents on early biologics like Humira continue expiring, biosimilars are flooding in at a fraction of the reference product's price, and that shift is turning what used to be the market's biggest constraint into one of its clearest growth opportunities. These lower-cost alternatives deliver comparable efficacy while making treatment reachable for patients who previously couldn't afford it, particularly in price-sensitive markets across Asia Pacific and Latin America.

Growing acceptance of biosimilars among regulators, physicians, and patients is opening the door to faster adoption, and as more clinical trials and regulatory approvals move through the pipeline, biosimilars stand to meaningfully expand both cost savings and access over the next several years. That expanding competition is also pushing established manufacturers to innovate further and compete harder on value, which, in a market this concentrated, is a genuinely healthy dynamic for patients.

Recent Developments:

• 2023: In October 2023, Novartis received FDA approval for the intravenous formulation of Cosentyx (secukinumab), extending treatment options for adults with ankylosing spondylitis, non-radiographic axial spondyloarthritis, and psoriatic arthritis.

• 2024: In September 2024, the FDA approved UCB's Bimzelx (bimekizumab) for active ankylosing spondylitis and non-radiographic axial spondyloarthritis, based on Phase 3 data from the BE MOBILE 1 and BE MOBILE 2 trials.

• 2024: In October 2024, Johnson & Johnson assumed full responsibility for marketing and distributing Remicade (infliximab) and Simponi (golimumab) in the United Kingdom, consolidating its control over two long-standing biologic franchises used across ankylosing spondylitis and related inflammatory conditions.

Ankylosing Spondylitis Market Key Players

• AbbVie Inc.

• Pfizer Inc.

• Novartis AG

• Johnson & Johnson (Janssen Pharmaceuticals)

• Eli Lilly and Company

• Amgen Inc.

• Bristol-Myers Squibb Company

• UCB S.A.

• Biogen Inc.

• Roche Holding AG

• Sanofi S.A.

• Merck & Co., Inc.

• Takeda Pharmaceutical Company Limited

• Gilead Sciences, Inc.

• Samsung Bioepis Co., Ltd.

• Sun Pharmaceutical Industries Ltd.

• Zydus Lifesciences Ltd.

• Dr. Reddy's Laboratories

• Hetero Drugs Ltd.

• Lupin Limited

Ankylosing Spondylitis Market Report Scope: